Using scans and blood tests to personalize lung cancer immunotherapy
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11324542
Using CT imaging and blood markers to predict which people with advanced non-small cell lung cancer will benefit from immunotherapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11324542 on ClinicalTrials.gov |
What this research studies
From a patient's perspective, this project uses routine chest CT scans plus blood samples to look for patterns that signal whether immunotherapy is likely to work. Researchers will extract detailed image features (radiomics) and combine them with blood-based biomarkers, then train biology-informed deep learning models that are designed to be more interpretable. The team plans to integrate the imaging and blood information to generate individual predictions of treatment benefit. The work focuses on noninvasive tests so results could be obtained without extra biopsies.
Who could benefit from this research
Good fit: People with advanced non-small cell lung cancer who are being considered for immune checkpoint inhibitor therapy and can provide recent CT scans and blood samples are the ideal candidates.
Not a fit: Patients with other cancer types, early-stage lung cancer not treated with immunotherapy, or those without available imaging or blood samples are unlikely to benefit from this project.
Why it matters
Potential benefit: Could help doctors choose immunotherapy more accurately, sparing patients ineffective treatment, reducing side effects, and saving cost.
How similar studies have performed: Previous studies using imaging features or blood biomarkers have shown promise but been inconsistent, so combining interpretable AI with blood tests represents a newer, promising approach.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, RUIJIANG — STANFORD UNIVERSITY
- Study coordinator: LI, RUIJIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.